Effectiveness and Safety of Apremilast in Immune Checkpoint Inhibitor-Associated Psoriasis
A Retrospective Multicenter Study From the EADV Task Force "Dermatology for Cancer Patients".
Koumaki D, Koumprentziotis IA, Apalla Z, Sibaud V, Starace MVR, Rapparini L, Segura S, Juan-Carpena G, Blanes-Martínez M, Oikonomou C, Delli F, Sotiriou E, Mayor A, Robles JL, Arenbergerová M, Nikolaou V
International Journal of DermatologyIn the feed 17 Jul 2026, published online 16 Jul 2026, issue 2026 Nov, added to PubMed 17 Jul 2026
Topics: PsoriasisDrug reactionsJAK inhibitors & other targeted pillsCancer drugs
Abstract
PubMed has no abstract for this paper, as is usual for research letters, correspondence and editorials. The publisher’s page has the full paper.
PMID 42464053 · DOI 10.1111/ijd.70592